0 is impossible... company only has $10 million in debt... $80 million in cash... very small float... the drug was a voluntary to limit liability to collect on E&O from the 0.02% deaths. Enterprise value on this beast is around $300 to $500 Million... They'll announce a few things this week:
1. Possible merger with another biotech giant.
2. They have the bandwidth to deal with this and get it back to market.
3. Sale of the company and all it's IP.
Too early to say they will file for BK. BK possibility in the next 3 months if this issue is not resolved.